The role of new antimicrobials for Gram-negative infections in daily clinical practice.
Anti-Bacterial Agents
/ therapeutic use
Anti-Infective Agents
/ therapeutic use
Azabicyclo Compounds
/ therapeutic use
Carbapenems
/ therapeutic use
Ceftazidime
/ therapeutic use
Cephalosporins
/ therapeutic use
Drug Combinations
Drug Resistance, Bacterial
Gram-Negative Bacterial Infections
/ drug therapy
Humans
Imipenem
/ therapeutic use
Microbial Sensitivity Tests
/ methods
Polymyxins
/ therapeutic use
Sisomicin
/ analogs & derivatives
Tazobactam
/ therapeutic use
Tetracyclines
/ therapeutic use
beta-Lactams
/ therapeutic use
Cefiderocol
Journal
Current opinion in infectious diseases
ISSN: 1473-6527
Titre abrégé: Curr Opin Infect Dis
Pays: United States
ID NLM: 8809878
Informations de publication
Date de publication:
12 2020
12 2020
Historique:
pubmed:
4
10
2020
medline:
10
7
2021
entrez:
3
10
2020
Statut:
ppublish
Résumé
To discuss a possible clinical reasoning for treating resistant Gram-negative bacteria (GNB) infections in daily clinical practice, as well as developing a research agenda for the field. Novel agents, both belonging to β-lactams and to other classes of antimicrobials, have recently become available, likely replacing polymyxins or polymyxin-based combination regimens as the preferred choices for the first-line treatment of severe resistant GNB infections in the near future. The peculiar characteristics of novel agents for severe resistant GNB infections have abruptly made the structure of previous therapeutic algorithms somewhat obsolete, in view of the differential activity of most of them against different classes of carbapenemases. Furthermore, other agents showing activity against resistant GNB are in late phase of clinical development. Optimizing the use of novel agents in order both to guarantee the best available treatment to patients and to delay the emergence and spread of resistance is an important task that cannot be postponed, especially considering the unavailability of well tolerated and fully efficacious options for treating resistant GNB infections that we faced in the last 15 years.
Identifiants
pubmed: 33009142
doi: 10.1097/QCO.0000000000000686
pii: 00001432-202012000-00011
doi:
Substances chimiques
Anti-Bacterial Agents
0
Anti-Infective Agents
0
Azabicyclo Compounds
0
Carbapenems
0
Cephalosporins
0
Drug Combinations
0
Polymyxins
0
Tetracyclines
0
avibactam, ceftazidime drug combination
0
beta-Lactams
0
ceftolozane, tazobactam drug combination
0
eravacycline
07896928ZC
Imipenem
71OTZ9ZE0A
Ceftazidime
9M416Z9QNR
plazomicin
LYO9XZ250J
Tazobactam
SE10G96M8W
Sisomicin
X55XSL74YQ
relebactam
Y1MYA2UHFL
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
495-500Références
FDA Drug Safety Communication. FDA warns of increased risk of death with IV antibacterial Tygacil (tigecycline) and approves new Boxed Warning. [accessed 24 Aug 2020]. Available at: https://www.fda.gov/drugs/drugsafety/ucm369580.htm.
Panidis D, Markantonis SL, Boutzouka E, et al. Penetration of gentamicin into the alveolar lining fluid of critically ill patients with ventilator-associated pneumonia. Chest 2005; 128:545–552.
Tsuji BT, Pogue JM, Zavascki AP, et al. International consensus guidelines for the optimal use of the polymyxins: endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Society of America (IDSA), International Society for Antiinfective Pharmacology (ISAP), Society of Critical Care Medicine (SCCM), and Society of Infectious Diseases Pharmacists (SIDP). Pharmacotherapy 2019; 39:10–39.
Bassetti M, Peghin M, Vena A, Giacobbe DR. Treatment of infections due to MDR Gram-negative bacteria. Front Med (Laussanne) 2019; 6:74.
Giacobbe DR, Mikulska M, Viscoli C. Recent advances in the pharmacological management of infections due to multidrug-resistant Gram-negative bacteria. Expert Rev Clin Pharmacol 2018; 11:1219–1236.
Karaiskos I, Lagou S, Pontikis K, et al. The ‘old’ and the ‘new’ antibiotics for MDR Gram-negative pathogens: for whom, when, and how. Front Public Health 2019; 7:151.
Bassetti M, Giacobbe DR, Vena A, Brink A. Challenges and research priorities to progress the impact of antimicrobial stewardship. Drugs Context 2019; 8:212600.
Mendelson M, Morris AM, Thursky K, Pulcini C. How to start an antimicrobial stewardship programme in a hospital. Clin Microbiol Infect 2020; 26:447–453.
Schweitzer VA, van Werkhoven CH, Rodriguez Bano J, et al. Joint Programming Initiative on Antimicrobial Resistance (JPIAMR) Working Group on Design of Antimicrobial Stewardship Evaluations. Optimizing design of research to evaluate antibiotic stewardship interventions: consensus recommendations of a multinational working group. Clin Microbiol Infect 2020; 26:41–50.
Alosaimy S, Abdul-Mutakabbir JC, Kebriaei R, et al. Evaluation of eravacycline: a novel fluorocycline. Pharmacotherapy 2020; 40:221–238.
Bilinskaya A, Linder KE, Kuti JL. Plazomicin: an intravenous aminoglycoside antibacterial for the treatment of complicated urinary tract infections. Expert Rev Anti Infect Ther 2020; 18:705–720.
Giacobbe DR, Bassetti M, De Rosa FG, et al. ISGRI-SITA (Italian Study Group on Resistant Infections of the Società Italiana Terapia Antinfettiva). Ceftolozane/tazobactam: place in therapy. Expert Rev Anti Infect Ther 2018; 16:307–320.
Pogue JM, Bonomo RA, Kaye KS. Ceftazidime/avibactam, meropenem/vaborbactam, or both? Clinical and formulary considerations. Clin Infect Dis 2019; 68:519–524.
Smith JR, Rybak JM, Claeys KC. Imipenem-cilastatin-relebactam: a novel beta-lactam-beta-lactamase inhibitor combination for the treatment of multidrug-resistant gram-negative infections. Pharmacotherapy 2020; 40:343–356.
Wu JY, Srinivas P, Pogue JM. Cefiderocol: a novel agent for the management of multidrug-Resistant Gram-negative organisms. Infect Dis Ther 2020; 9:17–40.
Dietl B, Martinez LM, Calbo E, Garau J. Update on the role of ceftazidime-avibactam in the management of carbapenemase-producing Enterobacterales. Future Microbiol 2020; 15:473–484.
Giani T, Antonelli A, Sennati S, et al. Results of the Italian infection-Carbapenem Resistance Evaluation Surveillance Trial (iCREST-IT): activity of ceftazidime/avibactam against Enterobacterales isolated from urine. J Antimicrob Chemother 2020; 75:979–983.
Stone GG, Seifert H, Nord CE. In vitro activity of ceftazidime-avibactam against Gram-negative isolates collected in 18 European countries, 2015–2017. Int J Antimicrob Agents 2020; 56:106045.
Vena A, Giacobbe DR, Castaldo N, et al. Clinical experience with ceftazidime-avibactam for the treatment of infections due to multidrug-resistant Gram-negative bacteria other than carbapenem-resistant enterobacterales. Antibiotics (Basel) 2020; 9:71.
Giani T, Arena F, Pollini S, et al. Pseudomonas aeruginosa Working Group. Italian nationwide survey on Pseudomonas aeruginosa from invasive infections: activity of ceftolozane/tazobactam and comparators, and molecular epidemiology of carbapenemase producers. J Antimicrob Chemother 2018; 73:664–671.
Sader HS, Carvalhaes CG, Duncan LR, et al. Susceptibility trends of ceftolozane/tazobactam and comparators when tested against European Gram-negative bacterial surveillance isolates collected during 2012–18. J Antimicrob Chemother 2020; doi: 10.1093/jac/dkaa278.
doi: 10.1093/jac/dkaa278
Bassetti M, Castaldo N, Cattelan A, et al. CEFTABUSE Study Group. Ceftolozane/tazobactam for the treatment of serious Pseudomonas aeruginosa infections: a multicentre nationwide clinical experience. Int J Antimicrob Agents 2019; 53:408–415.
Jorgensen SCJ, Trinh TD, Zasowski EJ, et al. Real-world experience with ceftolozane-tazobactam for multidrug-resistant Gram-negative bacterial infections. Antimicrob Agents Chemother 2020; 64:e02291–19.
Maraolo AE, Mazzitelli M, Trecarichi EM, et al. Ceftolozane/tazobactam for difficult-to-treat Pseudomonas aeruginosa infections: a systematic review of its efficacy and safety for off-label indications. Int J Antimicrob Agents 2020; 55:105891.
Pogue JM, Kaye KS, Veve MP, et al. Ceftolozane/tazobactam vs polymyxin or aminoglycoside-based regimens for the treatment of drug-resistant Pseudomonas aeruginosa. Clin Infect Dis 2020; 71:304–310.
Vena A, Giacobbe DR, Mussini C, et al. Clinical efficacy of ceftolozane-tazobactam versus other active agents for the treatment of bacteremia and nosocomial pneumonia due to drug resistant P. aeruginosa. Clin Infect Dis 2020; doi: 10.1093/cid/ciaa003.
doi: 10.1093/cid/ciaa003
Beirao EM, Rodrigues SDS, Andrade TK, et al. Activity of ceftolozane-tazobactam and comparators against Gram-negative bacilli: results from the study for monitoring antimicrobial resistance trends (SMART - Brazil; 2016–2017). Braz J Infect Dis 2020.
Lasko MJ, Nicolau DP. Carbapenem-resistant enterobacterales: considerations for treatment in the era of new antimicrobials and evolving enzymology. Curr Infect Dis Rep 2020; 22:6.
Shoulders BR, Casapao AM, Venugopalan V. An Update on Existing and Emerging Data for Meropenem-Vaborbactam. Clin Ther 2020; 42:692–702.
Johnston BD, Thuras P, Porter SB, et al. Activity of imipenem-relebactam against carbapenem-resistant escherichia coli isolates from the United States in relation to clonal background, resistance genes, coresistance, and region. Antimicrob Agents Chemother 2020; 64:e02408–19.
Karlowsky JA, Lob SH, Raddatz J, et al. In vitro activity of imipenem/relebactam and ceftolozane/tazobactam against clinical isolates of Gram-negative bacilli with difficult-to-treat resistance and multidrug-resistant phenotypes - SMART United States 2015–2017. Clin Infect Dis 2020.
Fraile-Ribot PA, Zamorano L, Orellana R, et al. Activity of imipenem-relebactam against a large collection of Pseudomonas aeruginosa clinical isolates and isogenic beta-lactam-resistant mutants. Antimicrob Agents Chemother 2020; 64:e02165–19.
Horner C, Mushtaq S, Livermore DM. BSAC Resistance Surveillance Standing Committee. Potentiation of imipenem by relebactam for Pseudomonas aeruginosa from bacteraemia and respiratory infections. J Antimicrob Chemother 2019; 74:1940–1944.
Young K, Painter RE, Raghoobar SL, et al. In vitro studies evaluating the activity of imipenem in combination with relebactam against Pseudomonas aeruginosa. BMC Microbiol 2019; 19:150.
Zhanel GG, Golden AR, Zelenitsky S, et al. Cefiderocol: a siderophore cephalosporin with activity against carbapenem-resistant and multidrug-resistant Gram-negative bacilli. Drugs 2019; 79:271–289.
Ito A, Nishikawa T, Ota M, et al. Stability and low induction propensity of cefiderocol against chromosomal AmpC beta-lactamases of Pseudomonas aeruginosa and Enterobacter cloacae. J Antimicrob Chemother 2018; 73:3049–3052.
Ito A, Sato T, Ota M, et al. In vitro antibacterial properties of cefiderocol, a novel siderophore cephalosporin, against Gram-negative bacteria. Antimicrob Agents Chemother 2018; 62:e01454–17.
Ito-Horiyama T, Ishii Y, Ito A, et al. Stability of novel siderophore cephalosporin S-649266 against clinically relevant carbapenemases. Antimicrob Agents Chemother 2016; 60:4384–4386.
Jacobs MR, Abdelhamed AM, Good CE, et al. ARGONAUT-I: activity of cefiderocol (S-649266), a siderophore cephalosporin, against Gram-negative bacteria, including carbapenem-resistant nonfermenters and enterobacteriaceae with defined extended-spectrum beta-lactamases and carbapenemases. Antimicrob Agents Chemother 2019; 63:e01801–18.
FDA Briefing Document. Meeting of the Antimicrobial Drugs Advisory Committee (AMDAC). October 16, 2019. Cefiderocol Injection (accessed 24 Aug 2020). Available at: https://www.fda.gov/media/131703/download.
Seifert H, Stefanik D, Sutcliffe JA, Higgins PG. In-vitro activity of the novel fluorocycline eravacycline against carbapenem nonsusceptible Acinetobacter baumannii. Int J Antimicrob Agents 2018; 51:62–64.
Sutcliffe JA, O’Brien W, Fyfe C, Grossman TH. Antibacterial activity of eravacycline (TP-434), a novel fluorocycline, against hospital and community pathogens. Antimicrob Agents Chemother 2013; 57:5548–5558.
Castanheira M, Deshpande LM, Woosley LN, et al. Activity of plazomicin compared with other aminoglycosides against isolates from European and adjacent countries, including Enterobacteriaceae molecularly characterized for aminoglycoside-modifying enzymes and other resistance mechanisms. J Antimicrob Chemother 2018; 73:3346–3354.
Zhanel GG, Lawson CD, Zelenitsky S, et al. Comparison of the next-generation aminoglycoside plazomicin to gentamicin, tobramycin and amikacin. Expert Rev Anti Infect Ther 2012; 10:459–473.
Withdrawal letter: Zemdri [accessed 24 August 2020]. Available at: https://www.ema.europa.eu/documents/withdrawal-letter/withdrawal-letter-zemdri_en.pdf.
Del Bono V, Giacobbe DR. Bloodstream infections in internal medicine. Virulence 2016; 7:353–365.
Deresinski S. Principles of antibiotic therapy in severe infections: optimizing the therapeutic approach by use of laboratory and clinical data. Clin Infect Dis 2007; 45: (Suppl 3): S177–S183.
Retamar P, Portillo MM, Lopez-Prieto MD, et al. SAEI/SAMPAC Bacteremia Group. Impact of inadequate empirical therapy on the mortality of patients with bloodstream infections: a propensity score-based analysis. Antimicrob Agents Chemother 2012; 56:472–478.
Dubourg G, Lamy B, Ruimy R. Rapid phenotypic methods to improve the diagnosis of bacterial bloodstream infections: meeting the challenge to reduce the time to result. Clin Microbiol Infect 2018; 24:935–943.
Giacobbe DR, Giani T, Bassetti M, et al. Rapid microbiological tests for bloodstream infections due to multidrug resistant Gram-negative bacteria: therapeutic implications. Clin Microbiol Infect 2019; 26:713–722.
Bassetti M, Peghin M. How to manage KPC infections. Ther Adv Infect Dis 2020; 7:2049936120912049.
Burillo A, Munoz P, Bouza E. Risk stratification for multidrug-resistant Gram-negative infections in ICU patients. Curr Opin Infect Dis 2019; 32:626–637.
Cano A, Gutierrez-Gutierrez B, Machuca I, et al. Risks of infection and mortality among patients colonized with Klebsiella pneumoniae carbapenemase-producing K. pneumoniae: validation of scores and proposal for management. Clin Infect Dis 2018; 66:1204–1210.
Giannella M, Pascale R, Gutierrez-Gutierrez B, et al. The use of predictive scores in the management of patients with carbapenem-resistant Klebsiella pneumoniae infection. Expert Rev Anti Infect Ther 2019; 17:265–273.